In a new guidance statement, the American Diabetes Association advises against the use of unapproved products, warning of ...

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...

The American Diabetes Association (ADA) urged healthcare providers against prescribing non-FDA approved compounded GLP-1 and ...

The American Diabetes Association is advising doctors and patients not to use compounded GLP-1s due to uncertainty about their content, safety, ...

Clinicians and patients should avoid using compounded GLP-1 products that are not FDA-approved, the American Diabetes Association wrote in a guidance statement published Dec. 2 in Diabetes Care. The ...

Earlier at ADA, Lilly reported phase 2 results with its once-daily oral GLP-1 agonist orforglipron, which achieved a weight reduction of almost 15% at 24 weeks, potentially giving Lilly the option ...

For instance, the ADA’s recommendation that GLP-1 receptor agonists, including semaglutide, may be used as first-line treatment in certain cases “is questionable, for several reasons” said Prof.

Medscape Medical News, June 25, 2024 ADA 2024 GLP-1 Kidney Benefits Seen With or Without SGLT2 Inhibitors Larger studies are needed because of the low numbers of patients on SGLT2 inhibitors in ...

Hanmi also presented follow-up nonclinical data on HM15275(LA-GLP-1/GIP/GCG), previously unveiled at the American Diabetes Association (ADA) conference. This novel anti-obesity candidate not only ...

and at ADA the drugmaker also reported mid-stage results with its oral candidate orforglipron, a non-peptide GLP-1 agonist. The study – published in the New England Journal of Medicine ...